Get the Stockscreener App
1.8051
0.82%
-0.0149
Sellas Life Sciences Group Inc stock is traded at $1.8051, with a volume of 3.26M.
It is down -0.82% in the last 24 hours and down -3.48% over the past month.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
See More
Previous Close:
$1.82
Open:
$1.84
24h Volume:
3.26M
Relative Volume:
1.12
Market Cap:
$190.06M
Revenue:
-
Net Income/Loss:
$-37.34M
P/E Ratio:
-1.3273
EPS:
-1.36
Net Cash Flow:
$-36.91M
1W Performance:
-6.96%
1M Performance:
-3.48%
6M Performance:
+3.74%
1Y Performance:
+51.68%
1-Day Range:
$1.73
$1.85
1-Week Range:
$1.73
$2.12
52-Week Range:
$0.772
$2.48
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
Name
Sellas Life Sciences Group Inc
Sector
Industry
Phone
(646) 200-5278
Address
7 TIMES SQUARE, NEW YORK, NY
Compare SLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
1.805 | 268.34M | 0 | -37.34M | -36.91M | -1.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.28 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
639.79 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.86 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.41 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.51 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-01-18 | Initiated | Oppenheimer | Outperform |
| Apr-02-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Upgrade | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc Stock (SLS) Latest News
SELLAS to present SLS009 data for relapsed leukemia at ASH meeting - Investing.com
SELLAS Life Sciences (NASDAQ: SLS) to present SLS009 with azacitidine and venetoclax in AML-MR at ASH 2025 - Stock Titan
SELLAS Life Sciences Group Inc. stock prediction for this weekLong Setup & Weekly High Return Stock Opportunities - newser.com
SELLAS Life Sciences Group Inc. stock trend forecastJuly 2025 PreEarnings & Long-Term Investment Growth Plans - newser.com
Analyzing SELLAS Life Sciences Group Inc. with risk reward ratio chartsJuly 2025 Momentum & Safe Investment Capital Preservation Plans - newser.com
Does SELLAS Life Sciences Group Inc. fit your quant trading modelQuarterly Trade Review & Safe Capital Investment Plans - newser.com
Should you wait for a breakout in SELLAS Life Sciences Group Inc.2025 Dividend Review & Daily Chart Pattern Signal Reports - newser.com
Can SELLAS Life Sciences Group Inc. stock sustain revenue growthJuly 2025 Reactions & Long-Term Growth Plans - newser.com
SELLAS Life Sciences Group Inc. stock outlook for YEAR2025 Stock Rankings & Community Consensus Stock Picks - newser.com
Does SELLAS Life Sciences Group Inc. show high probability of reboundJuly 2025 Sector Moves & Verified Stock Trade Ideas - newser.com
Understanding SELLAS Life Sciences Group Inc.’s price movementProduct Launch & Safe Entry Trade Signal Reports - newser.com
Is SELLAS Life Sciences Group Inc. reversing from oversold territory2025 Trading Recap & AI Driven Price Predictions - newser.com
Using economic indicators to assess SELLAS Life Sciences Group Inc. potentialJuly 2025 EndofMonth & Real-Time Market Sentiment Alerts - newser.com
Is SELLAS Life Sciences Group Inc. showing signs of accumulation2025 Price Momentum & Reliable Volume Spike Trade Alerts - newser.com
Can SELLAS Life Sciences Group Inc. (RXK3) stock hold up in economic slowdownTrade Risk Assessment & High Win Rate Trade Alerts - newser.com
What technical models suggest about SELLAS Life Sciences Group Inc.’s comeback2025 Volume Leaders & Advanced Swing Trade Entry Alerts - newser.com
Is SELLAS Life Sciences Group Inc. stock attractive for retirement portfoliosMarket Risk Analysis & Growth Focused Entry Reports - newser.com
Will SELLAS Life Sciences Group Inc. (RXK3) stock test record highs in 2025July 2025 Fed Impact & Consistent Profit Focused Trading Strategies - newser.com
How SELLAS Life Sciences Group Inc. stock valuations compare to rivalsMarket Performance Summary & AI Forecasted Entry and Exit Points - newser.com
Why Is SELLAS Life Sciences Stock Falling Today? - MSN
How institutional ownership impacts SELLAS Life Sciences Group Inc. stockInflation Watch & Breakout Confirmation Alerts - newser.com
Sellas Life Sciences Group Inc Stock (SLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):